
Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma
Faculty continue discussing how clinicians should interpret class-level and agent-level differences among CELMoDs when counseling community colleagues about treatment selection in relapsed/refractory multiple myeloma.
Episodes in this series

Faculty continue discussing how clinicians should interpret class-level and agent-level differences among CELMoDs when counseling community colleagues about treatment selection in relapsed/refractory multiple myeloma. The discussion highlights the activity of CELMoDs in patients with extensive prior lenalidomide exposure, while acknowledging that the evidence supporting sequential use of individual agents remains limited. Faculty debate whether iberdomide and mezigdomide should be viewed primarily as members of the same therapeutic class or as agents with potentially meaningful differences in potency and clinical activity. The panel also considers how differences in trial populations and combination partners influence treatment decisions. For example, EXCALIBER-RRMM and SUCCESSOR-2 enrolled patients with different prior anti-CD38 exposure and refractoriness, which may affect the applicability of their findings to individual patients. Faculty emphasize using available clinical evidence and treatment context when selecting a regimen, while recognizing that further data are needed to establish whether one CELMoD can provide meaningful benefit after progression on another.
Related to this article








